For Licensed Clinicians

Clinical case series

A structured, repeatable format for anonymized, de-identified clinical case write-ups in precision microbiome practice.

Real cases pending clinical review — all cases will be fully de-identified. The entries below are formatting placeholders only, not real patients or outcomes.

The case format

Every write-up follows the same six-part structure for consistency and review.

  • Case background — de-identified context only (age range, general setting). No names, dates, or identifying detail.
  • Presenting concerns — the symptoms and clinical questions that prompted microbiome testing.
  • Microbiome findings (high level) — functional-state classification and notable deviations, described at a summary level.
  • Intervention approach — the strategy at the approach level only. Never the recipe: no exact strains, no doses, no proprietary formulation detail.
  • Outcome / follow-up — observed change over the follow-up window, with honest limitations.
  • Clinician commentary — the ordering clinician’s interpretation and practice takeaways.

IP guardrail: clinical formulation recipes (exact strains and doses) are proprietary and must never appear in a published case. Keep interventions at the approach level (e.g. “a personalized multi-strain synbiotic targeting X”).

Example case template

Placeholder entries showing the structure. Replace bracketed fields with de-identified, clinically reviewed content.

Placeholder — Example A

Case [###] — [short de-identified descriptor]

Case background[De-identified patient, age range], [general clinical setting]. No identifying information.
Presenting concerns[presenting symptoms]; [duration]; [relevant history at a high level].
Microbiome findings (high level)[functional-state classification] with [notable high-level deviation]. Summary level only.
Intervention approachA personalized multi-strain synbiotic approach targeting [target / mechanism], alongside [non-recipe supportive measures]. No strains or doses listed — IP.
Outcome / follow-up[observed change] at [follow-up window]. Limitations: [honest caveats].
Clinician commentary[ordering clinician’s interpretation and takeaway].

Placeholder only — not a real patient. No diagnose / treat / cure claims; individual results are not generalizable.

Placeholder — Example B

Case [###] — [short de-identified descriptor]

Case background[De-identified patient, age range], [general clinical setting]. No identifying information.
Presenting concerns[presenting symptoms]; [duration].
Microbiome findings (high level)[functional-state classification] with [notable high-level deviation].
Intervention approachA personalized multi-strain synbiotic approach targeting [target / mechanism]. Approach level only — no recipe.
Outcome / follow-up[observed change] at [follow-up window], tracked with repeat testing.
Clinician commentary[ordering clinician’s interpretation].

Placeholder only — not a real patient.

How to read these cases

Case write-ups are individual clinical observations, not controlled evidence. There are no published randomized controlled trials of Flore formulations; the autism work is an open-label mSystems pilot, not an RCT. Cases are shared to illustrate a decision process, not to imply a guaranteed result, and nothing here diagnoses, treats, or cures any condition.

Flore’s platform context: work spanning 18,392 customers, roughly 23,000 microbiome tests and 40,000 formulations, drawing on 100+ formulation ingredients and 200+ conditions studied under IRB, with sequencing run in a CLIA/CAP laboratory. Flore was formerly Sun Genomics.